title: The possible perils of targeted therapy.
authors: Division of Pediatric Blood & Bone marrow Transplantation at Helen DeVos Children's Hospital, Grand Rapids, MI, USA.|Spectrum Health and Michigan State University, Department of Pediatrics & Human Development, Grand Rapids, MI, USA.
authors: U
authors: U
authors: Duffner
authors: Division of Pediatric Blood & Bone marrow Transplantation at Helen DeVos Children's Hospital, Grand Rapids, MI, USA.|Spectrum Health and Michigan State University, Department of Pediatrics & Human Development, Grand Rapids, MI, USA.
authors: A
authors: A
authors: Abdel-Mageed
authors: Division of Pediatric Blood & Bone marrow Transplantation at Helen DeVos Children's Hospital, Grand Rapids, MI, USA.
authors: J
authors: J
authors: Younge
authors: Division of Pediatric Blood & Bone marrow Transplantation at Helen DeVos Children's Hospital, Grand Rapids, MI, USA.
authors: C
authors: C
authors: Tornga
authors: Division of Pediatric Hematology/Oncology at Bronson Medical Center, Kalamazoo, MI, USA.
authors: K
authors: K
authors: Scott
authors: Division of Pediatric Hematology/Oncology at Bronson Medical Center, Kalamazoo, MI, USA.
authors: J
authors: J
authors: Staddon
authors: Division of Pediatric Hematology/Oncology at Bronson Medical Center, Kalamazoo, MI, USA.
authors: K
authors: K
authors: Elliott
authors: Spectrum Health and Michigan State University, Department of Pediatrics & Human Development, Grand Rapids, MI, USA.|Division of Pathology and Laboratory Medicine at Spectrum Health and Michigan State University, Grand Rapids, MI, USA.
authors: J
authors: J
authors: Stumph
authors: Spectrum Health and Michigan State University, Department of Pediatrics & Human Development, Grand Rapids, MI, USA.|Division of Pathology and Laboratory Medicine at Spectrum Health and Michigan State University, Grand Rapids, MI, USA.
authors: P
authors: P
authors: Kidd
mesh_terms: D018033:Antibodies, Bispecific / Q000009:adverse effects*; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects*; D005260:Female; D011495:Histone-Lysine N-Methyltransferase / Q000235:genetics; D006801:Humans; D007948:Leukemia, Monocytic, Acute / Q000209:etiology* / Q000235:genetics; D058990:Molecular Targeted Therapy / Q000009:adverse effects*; D051788:Myeloid-Lymphoid Leukemia Protein / Q000235:genetics; D016609:Neoplasms, Second Primary / Q000235:genetics* / Q000473:pathology; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D018033:Antibodies, Bispecific; D000074322:Antineoplastic Agents, Immunological; C497422:KMT2A protein, human; D051788:Myeloid-Lymphoid Leukemia Protein; C510808:blinatumomab; D011495:Histone-Lysine N-Methyltransferase